ABSTRACT
Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein report a case of AFOP with SLE and hemophagocytic syndrome. Early-phase high-resolution computed tomography showed a fine granular lung pattern. A pathological examination revealed AFOP. An immunohistological examination revealed numerous CD163+ and fewer CD68+ macrophages present in the lung tissue and in alveolar spaces as well, including fibrin balls, the interstitium, and bronchial walls. Pneumonia and thrombocytopenia worsened during high-dose steroid therapy, plasma exchange, and intravenous immunoglobulin administration. The addition of intravenous cyclophosphamide successfully ameliorated the symptoms and radiographic lesions. Therefore, this therapy may be useful for treating severe AFOP.
Subject(s)
Lupus Erythematosus, Systemic , Lymphohistiocytosis, Hemophagocytic , Pneumonia , Antigens, CD , Antigens, Differentiation, Myelomonocytic , Humans , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/diagnosis , Macrophages/pathology , Pneumonia/complications , Receptors, Cell SurfaceABSTRACT
Identifying new biomarkers beyond the established risk factors that make it possible to predict and prevent ischemic stroke has great significance. Extracellular vesicles are powerful cellâcell messengers, containing disease-specific biomolecules, which makes them powerful diagnostic candidates. Therefore, this study aimed to identify proteins derived from extracellular vesicles enriched serum related to future ischemic stroke events, using a proteomic method. Of Japanese subjects who voluntarily participated in health checkups at our institute a number of times, 10 subjects (6 males and 4 females, age: 64.2 ± 3.9 years) who developed symptomatic ischemic stroke (7.3 ± 4.4 years' follow-up) and 10 ageâsex matched controls without brain lesions (6.7 ± 2.8 years' follow-up) were investigated. Extracellular vesicles enriched fractions were derived from serum collected at the baseline visit. Differentially expressed proteins were evaluated using isobaric tagging for relative and absolute protein quantification (iTRAQ)-based proteomic analysis. Of the 29 proteins identified, alpha-2-macroglobulin, complement C1q subcomponent subunit B, complement C1r subcomponent, and histidine-rich glycoprotein were significantly upregulated (2.21-, 2.15-, 2.24-, and 2.16-fold, respectively) in subjects with future ischemic stroke, as compared with controls. Our study supports the concept of serum-derived extracellular vesicles enriched fractions as biomarkers for new-onset stroke. These proteins may be useful for prediction or for targeted therapy.
Subject(s)
Biomarkers , Extracellular Vesicles/metabolism , Ischemic Stroke/metabolism , Proteome , Proteomics , Aged , Biomarkers/blood , Chromatography, Liquid , Comorbidity , Disease Susceptibility , Enzyme-Linked Immunosorbent Assay , Female , Humans , Ischemic Stroke/diagnosis , Ischemic Stroke/etiology , Male , Middle Aged , Prognosis , Proteomics/methods , Risk Factors , Tandem Mass SpectrometryABSTRACT
Cystatin C (CST3) is an endogenous cysteine protease inhibitor, which is implicated in cerebral amyloid angiopathy (CAA). In CAA, CST3 is found to be aggregated. The purpose of this study is to investigate whether this aggregation could alter the activity of the protein relevant to the molecular pathology of CAA. A system of CST3 protein aggregation was established, and the aggregated protein was characterized. The results showed that CST3 aggregated both at 80 °C without agitation, and at 37 °C with agitation in a time-dependent manner. However, the levels of aggregation were high and appeared earlier at 80 °C. Dot-blot immunoassay for oligomers revealed that CST3 could make oligomeric aggregates at the 37 °C condition. Electron microscopy showed that CST3 could make short fibrillary aggregates at 37 °C. Cathepsin B activity assay demonstrated that aggregated CST3 inhibited the enzyme activity less efficiently at pH 5.5. At 7.4 pH, it lost the inhibitory properties almost completely. In addition, aggregated CST3 did not inhibit Aß1-40 fibril formation, rather, it slightly increased it. CST3 immunocytochemistry showed that the protein was positive both in monomeric and aggregated CST3-treated neuronal culture. However, His6 immunocytochemistry revealed that the internalization of exogenous recombinant CST3 by an astrocytoma cell culture was higher when the protein was aggregated compared to its monomeric form. Finally, MTT cell viability assay showed that the aggregated form of CST3 was more toxic than the monomeric form. Thus, our results suggest that aggregation may result in a loss-of-function phenotype of CST3, which is toxic and responsible for cellular degeneration.
Subject(s)
Amyloid beta-Peptides/metabolism , Amyloid/metabolism , Cystatin C/metabolism , Peptide Hydrolases/metabolism , Protein Aggregation, Pathological/metabolism , Humans , Hydrogen-Ion Concentration , Protein Aggregates , TemperatureABSTRACT
Transplantation with mesenchymal stem cells (MSCs) has been reported to promote functional recovery in animal models of ischemic stroke. However, the molecular mechanisms underlying the therapeutic effects of MSC transplantation have been only partially elucidated. The purpose of this study was to comprehensively identify changes in brain proteins in rats treated with MSCs for ischemic stroke, and to explore the multi-target mechanisms of MSCs using a proteomics-based strategy. Twenty-eight proteins were found to be differentially expressed following B10 MSC transplantation in adult male Wistar rats, as assessed using isobaric tagging for relative and absolute protein quantification (iTRAQ). Subsequent bioinformatic analysis revealed that these proteins were mainly associated with energy metabolism, glutamate excitotoxicity, oxidative stress, and brain structural and functional plasticity. Immunohistochemical staining revealed decreased expression of EAAT1 in the phosphate-buffered saline group as opposed to normal levels in the B10 transplantation group. Furthermore, ATP levels were also significantly higher in the B10 transplantation group, thus supporting the iTRAQ results. Our results suggest that the therapeutic effects of B10 transplantation might arise from the modulation of the acute ischemic cascade via multiple molecular pathways. Thus, our findings provide valuable clues to elucidate the mechanisms underlying the therapeutic effects of MSC transplantation in ischemic stroke.
Subject(s)
Ischemic Stroke/therapy , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/metabolism , Animals , Brain/metabolism , Brain/pathology , Brain Ischemia/metabolism , Disease Models, Animal , Ischemic Stroke/physiopathology , Male , Proteomics/methods , Rats , Rats, Wistar , Recovery of Function , Stroke/physiopathologyABSTRACT
We previously reported that Ag85B-expressing human parainfluenza type 2 virus (Ag85B-rHPIV2) was effective as a nasal vaccine against tuberculosis in mice; however, the mechanism by which it induces an immune response remains to be investigated. In the present study, we found that organogenesis of inducible bronchus-associated lymphoid tissue (iBALT) played a role in the induction of antigen-specific T cells and IgA antibody responses in the lung of mice intra-nasally administered Ag85B-rHPIV2. We found that expression of Ag85B was dispensable for the development of iBALT, suggesting that HPIV2 acted as an iBALT-inducing vector. When iBALT organogenesis was disrupted in Ag85B-rHPIV2-immunized mice, either by neutralization of the lymphotoxin pathway or depletion of CD11b+ cells, Ag85B-specific immune responses (i.e. IFN γ-producing T cells and IgA antibody) were diminished in the lung. Furthermore, we found that immunization with Ag85B-rHPIV2 induced neutrophil and eosinophil infiltration temporally after the immunization in the lung. Thus, our results show that iBALT organogenesis contributes to the induction of antigen-specific immune responses by Ag85B-rHPIV2 and that Ag85B-rHPIV2 provokes its immune responses without inducing long-lasting inflammation.
Subject(s)
Acyltransferases/immunology , Antigens, Bacterial/immunology , Lymphoid Tissue/immunology , Mycobacterium tuberculosis/immunology , Organogenesis , Parainfluenza Virus 2, Human/immunology , Tuberculosis Vaccines/immunology , Animals , Mice , Mice, Inbred C57BLABSTRACT
Cystatin C (CST3) is a cysteine protease inhibitor that regulates lysosomal enzyme activity and is reported to be involved in the process of neurodegeneration. In the present study, we investigated whether CST3 interacts with other proteins and affects neurodegeneration in vitro and under disease conditions. We intended to identify any protein that interacts with CST3 by using a yeast two-hybrid system, and found prosaposin (PSAP) as a candidate protein. The binding of CST3 and PSAP was confirmed using an immunoprecipitation-based in vitro assay. An enzyme activity assay revealed that PSAP ameliorated CST3-mediated inhibition of cathepsin B activity. To investigate further, CST3 and PSAP were co-expressed in HeLa cells and in a human neuronal cell line (A1). Subsequent immunocytochemical studies demonstrated that they were co-localized mainly in the lysosomes. In spinal motor neurons of autopsy cases, both proteins showed a granular staining pattern. However, the staining intensities of CST3 and PSAP decreased in Bunina body-positive motor neurons of patients with amyotrophic lateral sclerosis (ALS). Further analysis with immunofluorescence staining revealed that CST3 was immunopositive in the inclusions of ALS motor neurons, where it was closely associated, and sometimes co-localized, with PSAP. CST3 immunoreactivity is recognized as a marker for Bunina bodies in ALS, suggesting that PSAP might also be included in Bunina bodies. The interaction of CST3 and PSAP may alter their functions, leading to motor neuron degeneration in ALS.
Subject(s)
Amyotrophic Lateral Sclerosis/metabolism , Cystatin C/metabolism , Neurons/metabolism , Saposins/metabolism , Aged , Aged, 80 and over , Amyotrophic Lateral Sclerosis/pathology , Blotting, Western , Cathepsin B/metabolism , Cells, Cultured , Cystatin C/genetics , Female , Humans , Immunohistochemistry , Immunoprecipitation , Lipofuscin/metabolism , Male , Neurons/pathology , Saposins/genetics , Transfection , Two-Hybrid System TechniquesABSTRACT
The serotonin-1A (5-HT1A) receptor is strongly implicated in major depression and other affective disorders due to its negative regulation of serotonin neurone firing rates. Behavioural and clinical studies have repeatedly reported that the -1019G allele carries a high susceptibility for affective disorders. However, the underlying pathophysiology remains unknown. Here, we employed a genetic neuroimaging strategy in 99 healthy human subjects to explore the effect of serotonin-1A receptor polymorphism on brain resting-state functional connectivity (FC). We used functional magnetic resonance imaging, along with a seed-based approach, to identify three main brain networks: the default mode network (DMN), the salience network (SN) and the central executive network. We observed a significant decrease in the FC of the DMN within the dorsolateral and ventromedial prefrontal cortices in G-carriers. Furthermore, compared with the C-homozygote group, we observed decreased FC of the SN within the ventromedial prefrontal cortex and subgenual anterior cingulate cortex in the G-carrier group. Our results indicate that 5-HT1A receptor genetic polymorphism modulates the activity of resting-state FC within brain networks including the DMN and SN. These genotype-related alterations in brain networks and FC may provide novel insights into the neural mechanism underlying the predisposition for affective disorders in G allele carriers.
Subject(s)
Brain/metabolism , Depressive Disorder, Major/genetics , Receptor, Serotonin, 5-HT1A/genetics , Serotonin/genetics , Adult , Aged , Aged, 80 and over , Brain/diagnostic imaging , Brain/pathology , Brain Mapping , Depressive Disorder, Major/metabolism , Depressive Disorder, Major/pathology , Female , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/metabolism , Gyrus Cinguli/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neural Pathways/diagnostic imaging , Neural Pathways/metabolism , Neural Pathways/pathology , Polymorphism, Genetic , Receptor, Serotonin, 5-HT1A/metabolism , Serotonin/metabolismABSTRACT
Dendritic cells (DCs) play essential roles in both innate and adaptive immune responses. In addition, mutual regulation of the nervous system and immune system is well studied. One of neuropeptides, calcitonin gene-related peptide (CGRP), is a potent regulator in immune responses; in particular, it has anti-inflammatory effects in innate immunity. For instance, a deficiency of the CGRP receptor component RAMP 1 (receptor activity-modifying protein 1) results in higher cytokine production in response to LPS (lipopolysaccharide). On the other hand, how CGRP affects DCs in adaptive immunity is largely unknown. In this study, we show that CGRP suppressed Th1 cell differentiation via inhibition of IL-12 production in DCs using an in vitro co-culture system and an in vivo ovalbumin-induced delayed-type hypersensitivity (DTH) model. CGRP also down-regulated the expressions of chemokine receptor CCR2 and its ligands CCL2 and CCL12 in DCs. Intriguingly, the frequency of migrating CCR2(+) DCs in draining lymph nodes of RAMP1-deficient mice was higher after DTH immunization. Moreover, these CCR2(+) DCs highly expressed IL-12 and CD80, resulting in more effective induction of Th1 differentiation compared with CCR2(-) DCs. These results indicate that CGRP regulates Th1 type reactions by regulating expression of cytokines, chemokines, and chemokine receptors in DCs.
Subject(s)
Calcitonin Gene-Related Peptide/immunology , Dendritic Cells/immunology , Hypersensitivity, Delayed/immunology , Animals , B7-1 Antigen/immunology , Cell Differentiation/immunology , Chemokine CCL2/immunology , Down-Regulation/immunology , Interleukin-12/immunology , Mice , Mice, Inbred BALB C , Monocyte Chemoattractant Proteins/immunology , Receptor Activity-Modifying Protein 1/immunology , Receptors, CCR2/immunology , Th1 Cells/immunologyABSTRACT
Stachybotrydial, a triprenyl phenol metabolite from a fungus, has a plasminogen modulator activity selective to Glu-plasminogen. Stachybotrydial enhanced fibrin binding and activation of Glu-plasminogen (2- to 4-fold enhancement at 60-120 microM) but not of Lys-plasminogen. Approximately 1.2-1.6 moles of [3H]stachybotrydial bound to Glu-plasminogen to exert such effects. The selective modulation of the Glu-plasminogen function by stachybotrydial may be related to alteration of its conformational status.
Subject(s)
Benzofurans/pharmacology , Fibrin/metabolism , Plasminogen Activators/pharmacology , Plasminogen/metabolism , Spiro Compounds/pharmacology , Benzofurans/isolation & purification , Biotransformation/drug effects , Fibrin/drug effects , Fibrinolysin/metabolism , Fibrinolytic Agents/pharmacology , Humans , Molecular Conformation , Peptide Fragments/metabolism , Plasminogen Activators/isolation & purification , Protein Binding/drug effects , Spiro Compounds/isolation & purification , Stachybotrys/chemistry , Stachybotrys/metabolism , Tissue Plasminogen Activator/metabolism , Urokinase-Type Plasminogen Activator/metabolismABSTRACT
Three thiopeptide metabolites that enhance fibrin binding of plasminogen were isolated from a culture of Streptomyces sp. R1401. A combination of spectroscopic analyses revealed that these compounds were identical with the antibiotic A10255B, E and G. These agents enhanced fibrin binding of plasminogen and plasminogen/urokinase-mediated fibirinolysis at concentrations of 5 to approximately 20 microM. A10255B reversibily increased urokinase-catalyzed activation of plasminogen by lowering Km, while the agent did not enhance urokinase activity when substrates other than plasminogen were used, indicating that the agent affects plasminogen to increase its affinity to urokinase. A smaller but significant increase in activation was also observed when conformationally relaxed plasminogen derivatives such as Lys-plasminogen and mini-plasminogen were used. Two related thiopeptide antibiotics with a C-terminal amide had no effect on plasminogen activation, suggesting a role of the terminal carboxyl of the A10255 molecule in activity.